RY 167.32 0.7952% SHOP 156.84 0.1852% TD 87.295 0.6979% ENB 63.73 0.5522% BN 79.19 -0.1387% TRI 247.45 0.7082% CNQ 44.49 0.9301% CP 103.64 -1.267% CNR 140.22 -0.7573% BMO 140.7 0.8674% BNS 69.62 0.6069% CSU 4745.0 0.3269% CM 83.02 0.6791% MFC 45.15 0.512% ATD 70.57 0.6992% NGT 68.24 1.8052% TRP 70.02 -0.7653% SU 54.83 -0.4177% WCN 275.71 0.9224% L 195.87 1.6292%
Last update at 2025-03-25T18:39:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -53.01038M | -43.66618M | -44.57867M | -36.28600M | -38.15531M |
| Minority interest | - | - | - | - | - |
| Net income | -52.79595M | -44.16118M | -44.78492M | -36.69800M | -38.98031M |
| Selling general administrative | 16.17M | 17.31M | 14.65M | 12.74M | 11.30M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 1.25M | 14.94M | 3.15M | 3.46M | 1.14M |
| Reconciled depreciation | 1.81M | -1.77798M | 1.06M | 5.17M | 0.76M |
| Ebit | -53.22481M | -41.93409M | -45.04259M | -41.93459M | -38.69666M |
| Ebitda | -50.76714M | -43.71207M | -43.98513M | -36.76900M | -37.93665M |
| Depreciation and amortization | 2.46M | -1.77798M | 1.06M | 5.17M | 0.76M |
| Non operating income net other | - | - | - | 0.06M | 0.17M |
| Operating income | -53.22481M | -43.71207M | -45.04259M | -36.76900M | -38.69666M |
| Other operating expenses | 54.75M | 58.65M | 48.20M | 40.23M | 39.84M |
| Interest expense | 0.71M | 1.73M | 0.46M | 5.65M | 0.00000M |
| Tax provision | 0.00000M | 0.49M | 0.21M | 0.41M | 0.82M |
| Interest income | 0.93M | 0.05M | 0.46M | 0.42M | 0.38M |
| Net interest income | 0.21M | 0.05M | 0.46M | 0.42M | 0.38M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.21443M | 0.49M | 0.21M | 0.41M | 0.82M |
| Total revenue | 1.25M | 14.94M | 3.15M | 3.46M | 1.14M |
| Total operating expenses | 54.75M | 58.65M | 48.20M | 40.23M | 39.84M |
| Cost of revenue | - | - | - | 27.49M | 28.54M |
| Total other income expense net | 0.21M | 0.05M | 0.46M | 0.48M | 0.17M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -53.01038M | -44.16118M | -44.78492M | -36.69896M | -38.98031M |
| Net income applicable to common shares | -53.01038M | -44.16118M | -44.78492M | -36.69896M | -38.98031M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 61.53M | 91.28M | 83.40M | 99.53M | 71.61M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 1.24M | 0.84M | 0.95M | 1.24M | 0.86M |
| Total liab | 24.45M | 25.60M | 17.91M | 20.62M | 17.02M |
| Total stockholder equity | 37.09M | 65.68M | 65.49M | 78.91M | 54.58M |
| Deferred long term liab | - | - | - | 0.26M | - |
| Other current liab | 4.14M | 3.55M | 4.62M | 2.79M | 2.23M |
| Common stock | 0.05M | 0.04M | 0.03M | 0.03M | 0.03M |
| Capital stock | 0.05M | 0.04M | 0.03M | 0.03M | 0.03M |
| Retained earnings | -301.19000M | -250.45660M | -197.44621M | -153.28504M | -108.50012M |
| Other liab | - | - | - | 1.94M | 4.02M |
| Good will | - | - | - | - | - |
| Other assets | - | 3.39M | 3.01M | 3.12M | 3.38M |
| Cash | 48.51M | 51.61M | 64.37M | 74.87M | 44.29M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 17.08M | 11.55M | 12.79M | 16.32M | 11.66M |
| Current deferred revenue | 2.11M | - | 0.65M | 6.68M | 4.10M |
| Net debt | -33.81900M | -32.29856M | -54.31795M | -67.71992M | -38.49424M |
| Short term debt | 7.33M | 5.26M | 4.93M | 4.78M | 4.45M |
| Short long term debt | 3.96M | 1.96M | - | - | - |
| Short long term debt total | 14.70M | 19.32M | 10.05M | 7.15M | 5.80M |
| Other stockholder equity | 338.23M | 316.19M | 262.91M | 232.16M | 163.07M |
| Property plant equipment | - | 1.50M | 2.11M | 2.11M | 7.18M |
| Total current assets | 51.45M | 77.19M | 68.47M | 87.53M | 61.02M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 65.68M | 65.49M | 78.91M | 54.57M |
| Short term investments | 0.00000M | 24.67M | 0.00000M | 10.00M | 15.12M |
| Net receivables | 1.70M | 0.06M | 3.14M | 1.42M | 0.75M |
| Long term debt | 4.20M | 8.03M | - | - | - |
| Inventory | 0.00000M | - | - | - | 15.12M |
| Accounts payable | 3.50M | 2.73M | 2.59M | 2.07M | 0.88M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | -0.09587M | - | 0.00713M | -0.01032M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.04M | 0.03M | 0.03M | 0.03M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -250.45660M | -197.44621M | -153.28504M | -108.50012M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 2.81M | 3.39M | 3.01M | 3.12M | 3.40M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 10.08M | 14.10M | 14.93M | 12.01M | 10.58M |
| Capital lease obligations | 6.53M | 9.32M | 10.05M | 7.15M | 5.80M |
| Long term debt total | - | 8.03M | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -29.44534M | 10.00M | -9.94887M | -15.13432M | -39.50000M |
| Change to liabilities | -0.98747M | 2.35M | 1.30M | -0.71340M | 1.01M |
| Total cashflows from investing activities | -24.60988M | 9.11M | 4.46M | 3.45M | -20.35425M |
| Net borrowings | 14.56M | 10.00M | 10.00M | 10.00M | - |
| Total cash from financing activities | 53.66M | 19.23M | 58.61M | 50.79M | 4.18M |
| Change to operating activities | -2.16677M | -3.18281M | 1.15M | -3.85875M | 3.83M |
| Net income | -53.01038M | -44.16118M | -44.78492M | -36.69896M | -38.98031M |
| Change in cash | -12.75670M | -10.49533M | 30.58M | 23.44M | -42.58337M |
| Begin period cash flow | 64.52M | 75.02M | 44.44M | 21.00M | 63.58M |
| End period cash flow | 51.76M | 64.52M | 75.02M | 44.44M | 21.00M |
| Total cash from operating activities | -41.80595M | -38.83717M | -32.49403M | -30.79691M | -26.41097M |
| Issuance of capital stock | 39.30M | 17.38M | 56.68M | 49.00M | 4.17M |
| Depreciation | 1.81M | -1.77798M | 1.06M | 5.17M | 0.76M |
| Other cashflows from investing activities | 5.01M | 10.02M | 15.00M | 18.63M | 21.00M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | 4.79M | 4.85M | -0.50979M | - |
| Change to account receivables | 3.09M | -1.72504M | -0.66258M | -0.75490M | -0.75490M |
| Sale purchase of stock | 22.50M | 19.23M | -0.27105M | -0.09103M | 4.18M |
| Other cashflows from financing activities | 14.50M | 1.85M | 2.20M | 1.88M | 0.01M |
| Change to netincome | 9.50M | 11.49M | 9.92M | 6.58M | 7.52M |
| Capital expenditures | 0.17M | 0.91M | 0.60M | 0.05M | 1.85M |
| Change receivables | 3.09M | -1.72504M | -0.66258M | -0.75490M | - |
| Cash flows other operating | -1.02563M | -1.97992M | 0.59M | -0.01570M | 3.27M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -12.75670M | -10.49533M | 30.58M | 23.44M | -42.58337M |
| Change in working capital | 0.36M | -4.38746M | 1.23M | -1.48879M | 4.21M |
| Stock based compensation | 9.50M | 11.52M | 10.48M | 6.52M | 7.17M |
| Other non cash items | -0.45378M | -0.02613M | -0.56323M | -4.27754M | 0.35M |
| Free cash flow | -41.97670M | -39.75021M | -33.08929M | -30.84326M | -28.26521M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CUE Cue Biopharma |
-0.03 2.91% | 1.00 | - | - | 15.51 | 2.28 | 9.26 | -1.1035 |
| NVO Novo Nordisk A/S |
-1.75 2.32% | 73.58 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-0.86 1.15% | 73.82 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.3157 1.04% | 506.42 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-24.67 3.73% | 636.33 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
40 Guest Street, Boston, MA, United States, 02135
| Name | Title | Year Born |
|---|---|---|
| Mr. Daniel R. Passeri J.D., M.Sc., MSc. | CEO & Director | 1961 |
| Dr. Anish Suri Ph.D. | Pres & Chief Scientific Officer | 1974 |
| Ms. Kerri-Ann Millar | Chief Financial Officer | 1970 |
| Dr. Ronald D. Seidel III, Ph.D. | Co-Founder | 1976 |
| Dr. Rodolfo J. Chaparro | Co-Founder & Sr. Advisor | 1973 |
| Dr. Steven C. Almo | Co-Founder and Chairman of Scientific & Clinical Advisory Board | 1961 |
| George B. Zavoico Ph.D. | VP of Investor Relations & Corp. Devel. | NA |
| Mr. Colin G. Sandercock J.D., MSE | Sr. VP, Gen. Counsel & Sec. | 1957 |
| Dr. Kenneth J. Pienta M.D. | Acting Chief Medical Officer | 1960 |
| Dr. Matteo Levisetti M.D. | Sr. VP of Clinical Devel. | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA
AU
UK
US
NZ
Please wait processing your request...